Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a suite of powerful advancements that will significantly accelerate the next era of ...
Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient's cells.
New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has ...
A new whole genome platform integrates on-flow cell library prep and advanced informatics to deliver comprehensive variant ...
14d
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing
In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome solution and expanded clinical sequencing services, including supporting Florida State University’s new pediatric rare ...
The promise of genome editing to help understand human diseases and create new therapies is vast, but technological limitations have limited advancement of the field. While existing editing ...
Researchers found that Neanderthals carried excess modern human DNA on their X chromosomes, pointing to predominantly male ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results